Beijing Deli Furui Pharmaceutical Technology Co. Ltd.

Primary Objective: This study used a randomized, open-label, four-sequence, four-period, fasting and fed dosing design to compare the exposure of celecoxib tablets (I) developed by Beijing Delishena Pharmaceutical Technology Co., Ltd. and manufactured by Anhui Sihuan Kebao Pharmaceutical Co., Ltd., and celecoxib capsules (Celebrex®) manufactured by Pfizer Pharmaceuticals LLC, under fasting and fed conditions in healthy volunteers. The food effect of celecoxib tablets (I) and celecoxib capsules under fasting and fed conditions was also evaluated. Secondary Objective: To observe the safety of a single oral dose of the test drug and the control drug in healthy volunteers.

Main purpose: To use docetaxel injection concentrate (self-emulsifying type) (specification: 1mL: 20mg) developed and produced by Beijing Deli Yingjie Pharmaceutical Technology Co., Ltd. as the test preparation, and docetaxel injection (specification: 0.5mL: 20mg, Taxotere®) produced by Sanofi-Aventis Deutschland GmbH as the reference preparation, and conduct an in vivo pharmacokinetic comparison study in accordance with the relevant provisions of the bioequivalence test to investigate the pharmacokinetic behavior of docetaxel in patients diagnosed with malignant tumors and ready to receive docetaxel chemotherapy, and evaluate the bioequivalence of the two preparations. Secondary purpose: To study the safety of the test preparation docetaxel injection concentrate (self-emulsifying type) and the reference preparation docetaxel injection (trade name: Taxotere®) in patients diagnosed with malignant tumors and ready to receive docetaxel chemotherapy

Primary Objective: This study used a randomized, open-label, four-sequence, four-period, fasting and fed dosing design to compare the exposure of two celecoxib tablets (I) (70 mg/tablet), developed by Beijing Delishena Pharmaceutical Technology Co., Ltd. and manufactured by Anhui Sihuan Kebao Pharmaceutical Co., Ltd., to one celecoxib capsule (200 mg/capsule, Celebrex®), manufactured by Pfizer Pharmaceuticals LLC, under fasting and fed conditions in healthy volunteers. The food effect of celecoxib tablets (I) and celecoxib capsules was also evaluated under fasting and fed conditions. Secondary Objective: To observe the safety of a single oral dose of the test drug and the control drug in healthy volunteers.